Product Details

ZYNRELEF 200MG ER SLN SDV EA

Manufacturer: HERON THERAPEUTICS, INC

MFG#: 47426-0303-01

NDC: 47426-0303-01

PID: 418724

1/EA

$313.53

Limited Quantities
$313.53

Additional Information

Product NameZynrelef 200Mg Er Sln Sdv Ea
ApplicationLocal Anesthetic
Generic Drug NameBupivacaine / Meloxicam
Mechanism of ActionProvides local anesthesia via nerve signal blockade (Bupivacaine) and reduces inflammation (Meloxicam).
Dosage FormSolution
Strength200 mg (Bupivacaine) - 6 mg (Meloxicam)
TypeExtended Release
Volume7 mL
Route of AdministrationApplied directly to the surgical site during the procedure by a healthcare professional.
Duration of ActionProvides analgesia for up to 72 hours post-surgery.
Side EffectsNausea, dizziness, constipation, vomiting, and local site reactions.
Pediatric UseNot approved for use in pediatric patients.
ContraindicationsAvoid use in patients with known hypersensitivity to amide-type local anesthetics or NSAIDs.
PackagingPackaged as a single-dose vial containing 7 mL of extended-release solution.
UsesIndicated for postsurgical analgesia in soft tissue and orthopedic procedures.

Description

Zynrelef 200 mg Extended-Release Solution is a post-surgical analgesic designed to provide prolonged pain relief for up to 72 hours following surgical procedures. It is specifically indicated

for use in adults undergoing soft tissue and orthopedic surgeries, including foot and ankle procedures and other orthopedic surgeries such as total joint arthroplasty, provided direct exposure to articular cartilage is avoided.

The active ingredients in Zynrelef include bupivacaine and meloxicam, which work synergistically to provide extended pain relief. Bupivacaine is a local anesthetic that blocks nerve signals in the area of administration, while meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that reduces inflammation and pain. The combination of these two agents ensures both immediate and sustained pain control, improving post-surgical recovery and patient comfort.

Zynrelef is administered as a single dose directly into the surgical site by a healthcare professional during the procedure. Its extended-release formulation allows for a controlled release of the active ingredients over a 72-hour period, minimizing the need for additional pain relief medications and potentially reducing opioid use in post-operative care.

Product Properties:

Description -
DESI Drug Ind -
DESI2 Drug Ind NR
Drug Category -
Drug Type Code S
FDA Approval Date 07/01/2021
FDA Therap Equiv ML
HCPCS Instill bupivac and meloxic, 1 mg-0.03mg
Market Entry Date -
Medical Coverage C9088
Termination Date 1
Unit 7
Units Per Pkg 05/12/2021
Active Ingredients 5054 bupivacaine 38396393; 6272 meloxicam 71125387
AHFS Class 72000000 LOCAL ANESTHETICS (PARENTERAL); 28080492 OTHER NONSTEROIDAL ANTI-INFLAM. AGENTS
DEA Class NC
Dose Form SOLUTION,EXTENDED RELEASE VIAL (ML)
Fine Line Class 850085008510 All Rx Products
Gen Code and Des 82299 bupivacaine/meloxicam IMPLANT SOLER VIAL 200-6 MG/7
Inactive Ingredients -
OMP Family -
Product Category RX Pharmaceuticals
Strength 200/6MG
Allocation Period -
Case Quantity 30
Drug Form Pack Size 7
Form SINGLE DOSE VIAL
Hazard Code -
Listed Chemical -
NIOSH Code -
Orange Book ZC Pharmaceutical entity and labeler evaluated but no therapeutic equivalence rating given. Usually applies to single source drugs.
Retail Pack Quantity 1
Returnable Status Returnable
Special Storage Cond 00 None
Temp Zone 10 Room Temperature
Unit EA
Unit Size 7

Frequently Asked Questions (FAQs)

The cost of ZYNRELEF 200MG ER SLN SDV EA is $$313.53

ZYNRELEF 200MG ER SLN SDV EA is manufactured by HERON THERAPEUTICS, INC.

You can purchase ZYNRELEF 200MG ER SLN SDV EA on our website at https://supplies.pipelinemedical.com/product/detail/zynrelef-200-6-mg-sdv-kit-7-ml-228883